3rd Circ. To Review Venue Ruling In GSK Birth Defects Case
The Third Circuit agreed Friday to allow plaintiffs in a suit alleging GlaxoSmithKline PLC's antidepressant drug Paxil caused birth defects to appeal the company's removal of the case to federal court...To view the full article, register now.
Already a subscriber? Click here to view full article